Phys Clinical Cases · oncological
Breast Cancer — Clinical Case
DCE long case for breast cancer: a 62-year-old woman who is 7 years post-diagnosis of ER-positive breast cancer, presenting as a breast cancer survivor with new-onset bone pain from metastatic recurrence. Full patient assessment, SASPOP opening, structured problem list, integrated management plan (the metastatic ER-positive bone-only disease strategy, CDK4/6 inhibitor plus endocrine therapy, bone-targeted therapy with zoledronic acid, palliative radiotherapy, cardiotoxicity and osteoporosis from prior aromatase inhibitor therapy, and the psychosocial dimensions of recurrence after years of survivorship), and probing examiner questions.
16 min readVerification in progress
On this page
Study tools
Target exams
FRACP DCEMRCP PACES
Prompt
DCE long case for breast cancer: a 62-year-old woman who is 7 years post-diagnosis of ER-positive breast cancer, presenting as a breast cancer survivor with new-onset bone pain from metastatic recurrence. Full patient assessment, SASPOP opening, structured problem list, integrated management plan (the metastatic ER-positive bone-only disease strategy, CDK4/6 inhibitor plus endocrine therapy, bone-targeted therapy with zoledronic acid, palliative radiotherapy, cardiotoxicity and osteoporosis from prior aromatase inhibitor therapy, and the psychosocial dimensions of recurrence after years of survivorship), and probing examiner questions.
Breast Cancer — Clinical Case
References4ShowHide
- [1]Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin, 2024.PMID 38572751
- [2]Loblaw DA, Perry J, Chambers A, et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression J Clin Oncol, 2005.PMID 15774794
- [3]Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet, 2005.PMID 15639680
- [4]Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib Improves Disease-Free Survival in Early, High-Risk, BRCA-Mutated, HER2- Breast Cancer Oncologist, 2021.PMID 34152054